Molecular Partners Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Molecular Partners Stock Summary

Molecular Partners competes with Surrozen, Armata Pharmaceuticals, Pasithea Therapeutics, Aditxt, and Scpharmaceuticals. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Molecular Partners operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people.

Molecular Partners Key Financial Ratios

Molecular Partners Key Balance Sheet Accounts

Molecular Partners Key Income Statement Accounts

Molecular Partners Key Cash Accounts

Molecular Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Molecular Partners's current stock value. Our valuation model uses many indicators to compare Molecular Partners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Partners competition to find correlations between indicators driving Molecular Partners's intrinsic value. More Info.Molecular Partners AG is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Molecular Partners' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Molecular Partners' earnings, one of the primary drivers of an investment's value.

Molecular Partners Systematic Risk

Today, most investors in Molecular Partners Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Molecular Partners' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Molecular Partners growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Molecular Partners help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Molecular Partners AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Molecular Partners AG based on widely used predictive technical indicators. In general, we focus on analyzing Molecular Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Molecular Partners's daily price indicators and compare them against related drivers.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.